SAN FRANCISCO, Aug. 30, 2016 -- Zephyr Health, the leading Insights-as-a-Service solution provider to Life Sciences companies, today launched two new, game changing analytic capabilities for Zephyr IlluminateTM. These new capabilities, Referral Analytics and Segment Analytics, previously available only for charter customers, are the latest addition to its enterprise solution that integrates thousands of disparate data sources to create precise and predictive insights.
Referral Analytics is the industry’s most innovative, machine-driven solution that identifies referral patterns to help predict and segment potential referring healthcare providers, specialists or organizations. With Referral Analytics, life sciences companies can quickly compare historical referral trends and volume, and prioritize existing or new customers based upon referral potential.
Segment Analytics provides a summary view of multiple customer groups to better analyze and target key customers and markets. Using Zephyr Illuminate’s powerful, proprietary scoring capabilities, Segment Analytics aggregates data relevant to both medical and commercial teams on key attributes such as treatment, promotional engagement, marketing influence and clinical research.
“These new capabilities prove the transformational power big data has for a life sciences business,” said William King, Founder and Executive Chairman, Zephyr Health. “With these new capabilities our customers are significantly improving their outreach strategies by easily extracting these meaningful insights - like finding the highest ranking potential referrers, or high potential treaters with low engagement - all in Zephyr Illuminate’s simple user interface.”
Zephyr Illuminate™ was cited as a vertical specialist among insights solutions providers in the May 2016 Forrester Research Report, Vendor Landscape: Insights Service Providers. Fortune 100 life sciences companies are using Zephyr Illuminate to optimize product planning, launch and sales by engaging the right physicians, accounts and institutions using insights from global health data.
About Zephyr Health
Zephyr Health helps life sciences companies – pharmaceutical, biotech, medical device and diagnostics – engage the right physicians, accounts and institutions using insights from global health data. Zephyr Illuminate™ is a leading Insights-as-a-Service solution that integrates thousands of data sources to create precise and predictive insights. From pre-launch to product maturity, life sciences companies can make confident decisions faster with data-driven targeting and deep customer profiles. Zephyr Health's customers include Top 10 Pharmaceutical companies, Top 10 Biotech Companies and Top 10 Medical Device companies.
Zephyr Health is a privately held company headquartered in San Francisco with offices in London, UK, and Pune, India. Zephyr Health is venture backed by Google Ventures, Kleiner Perkins Caufield & Byers and Icon Ventures. For more information, please visit: www.zephyrhealth.com.
Media Contact: Zephyr Health Global Communications [email protected]


Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Instagram Outage Disrupts Thousands of U.S. Users
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 



